NFIB Fusion

CI-VAR-00001442Explore in graph →CIViC 5051

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DOID:00802023unmapped disease
MYB::NFIB Fusion	Linsitinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12164 In a study of oncogenic signalling pathways, tumours and cultured cells from 15 patients with MYB-NFIB translocation-positive adenoid cystic carcinoma (ACC) were analyzed. Treatment with linsitinib, a… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC	civic
MYB::NFIB Fusion	Crizotinib + Gefitinib + LinsitinibCombination	Predictive	B	Supports Sensitivity Response	2	submitted	EID12167 Treatment of ACC cells with a combination of linsitinib, crizotinib, and gefitinib resulted in synergistic inhibition of cell proliferation (p = 0.004). This combination also significantly downregulat… (full text at CIViC) PMID 28954282 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.